Gallery
Photos from events, contest for the best costume, videos from master classes.
 |  |
 |  |
 |  |
 |  |
 |  |
 |  |
Gabapentin was not found to be effective over placebo in a comprehensive network meta-analysis of pharmacologic treatments in acute mania [8]. Systematic reviews of gabapentin treatment in psychiatric and/or substance use disorders showed inconclusive evidence for efficacy in BD, but possible efficacy for some anxiety disorders [9, 10]. Explore gabapentin's role in mental health treatment, including its uses, benefits, and potential risks. Learn about dosage, effectiveness, and side effects. Gabapentin, known by the brand name Neurontin, is a drug that’s sometimes prescribed for uses beyond what it’s approved for. For example, although it’s approved by the Food and Drug Administration (FDA) to treat seizures and nerve pain, it may be prescribed off-label for chronic muscle pain (fibromyalgia), generalized anxiety disorder, and alcohol withdrawal, among other uses. While some Abstract Objective This article reviews evidence-based psychiatric uses of gabapentin, along with associated risks. Method of Research An extensive literature review was conducted, primarily of articles searchable in PubMed, relating to psychiatric uses, safety, and adverse effects of gabapentin. Results Evidence supports gabapentin as a treatment for alcohol withdrawal and alcohol use From the data presented, gabapentin cannot be recommended for treatment of bipolar disorder. Further studies are required to determine whether gabapentin has any role in the management of bipolar disorder. The use of gabapentin in bipolar disorder (BPD) treatment provides an informative case of off-label uptake and abandonment of a new medication. Gabapentin was patented by Warner-Lambert in 1977 and FDA-approved in December1993 for the adjunctive treatment of epilepsy and in 2002 for postherpetic neuralgia (see Appendix 1 for timeline). Gabapentin may be a useful drug for the add-on treatment of bipolar patients with poor response to other mood stabilizers. Gabapentin may improve depressive residual symptoms such as irritability, social withdrawal or anxiety. These results should be confirmed in randomized clinical trials. A systematic search strategy employing different combinations of the keywords (bipolar, mania, hypomania, gabapentin, neurontin, gralise, gabarone, fanatrex, pregabalin, lyrica) was developed and performed in five databases namely OVID Medline, PubMed, ProQuest, PsychInfo and ScienceDirect from database inception to 7 June 2021. Unfortunately, gabapentin does not demonstrate efficacy in randomized trials for bipolar disorder and current treatment guidelines do not emphasize its use. Despite of the lack of evidence, reviews of gabapentin prescribing patterns in the United States show that this medication is still being used with alarming frequency for bipolar disorder. Results: Gabapentin was moderately to mark-edly effective in 30% (15/50) of patients, with statistically nonsignificant differences between patients with bipolar disorder type I, bipolar dis-order type II and NOS, and unipolar major de-pressive disorder. 70% reported side effects, mainly sedation, with 16% of the total sample discontinuing treatment due to adverse events. Conclusion Key takeaways: Gabapentin is a medication that’s used to treat seizures, nerve pain from shingles, and restless leg syndrome. Despite previous marketing claims, there’s no evidence that gabapentin is a good treatment for bipolar disorder. The best treatment for bipolar disorder is therapy and a combination of other medications. These include mood stabilizers, anticonvulsants, and Conclusion Gabapentin may be a useful drug for the add-on treatment of bipolar patients with poor response to other mood stabilizers. Gabapentin may improve depressive residual symptoms such as irritability, social withdrawal or anxiety. These results should be confirmed in randomized clinical trials. Two new anticonvulsants, lamotrigine and gabapentin, have been used increasingly for bipolar disorder in the past several years. Despite this array of options, bipolar disorder remains a difficult disorder to treat. Some subtypes, such as those characterized by rapid cycling or mixed episodes, have been especially resistant to lithium treatment. Gabapentin is a nerve pain medication and anticonvulsant that has proven to be effective for people who have hard-to-treat depression or other mood disorders. Gabapentin is commonly used off-label in the treatment of psychiatric disorders with success, failure, and controversy. A systematic review of the literature was performed to elucidate the evidence for clinical benefit of gabapentin in psychiatric Systematic reviews of gabapentin treatment in psychiatric and/or substance use disorders showed inconclusive evidence for efficacy in BD, but possible efficacy for some anxiety disorders [9, 10]. Gabapentin, a medication commonly used to treat seizures and nerve pain, has also been explored as a potential treatment for bipolar disorder. Research suggests that gabapentin may help alleviate symptoms of bipolar disorder, particularly in patients who have not responded to traditional treatments. What is Bipolar Disorder? Abstract Background: Gabapentin, a new anti-epileptic agent, has been anecdotally reported to be effective in the treatment of mania. We systematically assessed the response rate in bipolar patients being treated adjunctively with gabapentin for manic symptoms, depressive symptoms, or rapid cycling not responsive to standard treatments. Prescribing-Based Evidence To facilitate learning, I have at-tached whimsical names to all the pru-dent options available to the prescriber to treat bipolar spectrum disorders while the experts clarify the data and remove the controversy (Table 1). Anticonvulsants: Perhaps one of the reasons so many anticonvulsants that are not well documented to have efficacy in bipolar disorder are never
Articles and news, personal stories, interviews with experts.
Photos from events, contest for the best costume, videos from master classes.
| |
| |
| |
| |
| |
| |